HAVN Life Session at Psychedelic Capital: Jan 2022 by Microdose
HAVN Life Session at Psychedelic Capital: Jan 2022 by Microdose
Tim Moore and Michael Zavet to speak on Thursday, January 27 at 4:25pm EST
蒂姆·摩爾和邁克爾·扎維特將於美國東部時間1月27日星期四下午4點25分發表講話
Vancouver, British Columbia--(Newsfile Corp. - January 27, 2022) - HAVN Life Sciences Inc. (CSE: HAVN) (OTC Pink: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life"), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is announcing that CEO Tim Moore will be hosting a virtual session at the upcoming Psychedelic Capital: Jan 2022 conference presented by Microdose on Thursday, January 27th, 2022 at 4:25 PM EST.
温哥華，不列顛哥倫比亞省-(Newsfile Corp.-2022年1月27日)-HAVN生命科學公司。(CSE：擁有)(場外粉色：HAVLF)(FSE：5NP)致力於標準化提取迷幻化合物以創造支持大腦健康和增強智力能力的原料藥的生物技術公司HAVN Life(“The Company”或“HAVN Life”)宣佈，首席執行官蒂姆·摩爾(Tim Moore)將在即將舉行的迷幻資本：2022年1月22日(星期四)美國東部時間下午4：25召開的會議上主持一場虛擬會議。
The live, online event will give attendees an opportunity to interact with C-Suite executives from the top companies in the industry, as well as get insight on the latest IPOs, newest opportunities & deepest insights in the psychedelic industry.
現場直播的在線活動將讓與會者有機會與行業頂尖公司的高管互動，並洞察迷幻行業的最新IPO、最新機會和最深刻的見解。
HAVN Life CEO, Tim Moore will be joined by Michael Zavet, CEO of Spore Life Sciences Inc. ("Spore") for a fireside chat about HAVN Life's recent Definitive Agreement to acquire Spore and the strategic partnership between the Company and Spore.
HAvn Life首席執行官蒂姆·摩爾(Tim Moore)將與孢子生命科學公司(Sporate Life Science Inc.)首席執行官邁克爾·扎維特(Michael Zavet)一起在爐邊聊天，討論哈文人壽最近達成收購孢子的最終協議以及公司與孢子之間的戰略合作伙伴關係。
Mr. Moore will also be discussing HAVN Life's steady growth over the past year and 2022 milestones the company is working towards. The session will give existing shareholders and the investment community a unique opportunity to get an insider look at the company's blueprint for the coming year, as well as ask questions during a Q & A session.
摩爾還將討論HAVN Life在過去一年中的穩步增長以及該公司正在努力實現的2022年裏程碑。這場會議將為現有股東和投資界提供一個獨特的機會，讓他們瞭解公司來年的藍圖，並在問答環節提出問題。
DATE: Thursday, January 27, 2022
TIME: 4:25pm EST
日期：2022年1月27日(星期四)
時間：美國東部時間下午4：25
Get Free Tickets HERE or use promo code HAVNLIFE during checkout.
獲取免費門票此處或使用促銷代碼HAVNLIFE在結賬時。
While the presentation is live streamed, lifetime access to recordings will be available to all ticket holders. Click here for conference agenda details.
雖然演示文稿是現場直播的，但所有持有門票的人都可以終身觀看錄音。單擊此處查看會議議程詳細信息。
###
###
About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.
關於HAVN生命科學公司
HAVN生命科學公司是一家生物技術公司，致力於標準化提取迷幻化合物，用於原料藥的創建、天然保健品的開發以及支持大腦健康和增強智力能力的創新療法。
Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
通過其研究部門HAVN Labs，該公司開發了標準化的、自然衍生的迷幻化合物的端到端供應鏈，用於將定義現代醫學未來的研究。憑藉其新的天然保健品系列，HAVN Life提供全方位的高質量蘑菇和植物提取物，幫助增強免疫功能，減少炎症，支持健康的生活方式。
Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.
購買我們的產品並在Your havnlife.com上了解更多信息，並在Facebook、Twitter、Instagram和YouTube上關注我們。
Contact:
聯繫方式：
Investor Relations: ir@havnlife.com 604 687-7130
Media: savi@emergence-creative.com 647 896-8078
投資者關係部：ir@havnlif.com 604 687-7130
媒體：Savi@Emerging-Creative.com 647 896-8078
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the strategic partnership between the Company and Spore (the "Strategic Partnership") and the Company and its business, products and future of the Company's business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that the Strategic Partnership will not be completed as contemplated, or at all, the risk that the anticipated benefits of the Strategic Partnership will be not realized as contemplated, or at all, and risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.
前瞻性信息：本新聞稿包含適用證券法所指的“前瞻性信息”，這些信息與有關公司與孢子公司之間的戰略夥伴關係(“戰略夥伴關係”)和公司及其業務、產品和公司業務未來的陳述有關。儘管公司認為前瞻性信息中反映的預期是合理的，但不能保證這些預期將被證明是正確的。提醒讀者不要過度依賴前瞻性信息。這些前瞻性陳述會受到風險和不確定因素的影響，這些風險和不確定因素可能會導致實際結果、業績和發展與這些陳述中預期的大不相同，這些風險主要取決於戰略夥伴關係不能按預期完成的風險，或者根本不能實現戰略夥伴關係的預期利益的風險，以及公司的產品和計劃與本新聞稿中陳述的產品和計劃不同以及公司可能無法按預期執行其業務計劃的風險。除法律另有規定外，公司明確表示不承擔任何義務，不打算更新本新聞稿中的任何前瞻性陳述或前瞻性信息。儘管公司認為前瞻性信息中反映的預期是合理的，但不能保證這些預期將被證明是正確的。本新聞稿中的陳述是截至本新聞稿發佈之日作出的。
The CSE has not reviewed, approved or disapproved the content of this press release
CSE未審核、批准或不批准本新聞稿的內容
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。